US 12,077,527 B2
Compositions and methods for inhibiting ACSS2
Philipp Mews, New York, NY (US); Shelley L Berger, Wayne, PA (US); Jeffrey D. Winkler, Wynnewood, PA (US); Andrew Glass, Philadelphia, PA (US); and Simon David Peter Baugh, Ringoes, NJ (US)
Assigned to The Trustees of the University of Pennsylvania, Pennsylvania, PA (US)
Appl. No. 16/650,901
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
PCT Filed Sep. 26, 2018, PCT No. PCT/US2018/052839
§ 371(c)(1), (2) Date Mar. 26, 2020,
PCT Pub. No. WO2019/067528, PCT Pub. Date Apr. 4, 2019.
Claims priority of provisional application 62/563,148, filed on Sep. 26, 2017.
Prior Publication US 2020/0291005 A1, Sep. 17, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 241/44 (2006.01); A61K 31/498 (2006.01); A61P 25/00 (2006.01); C07D 409/14 (2006.01)
CPC C07D 409/14 (2013.01) [A61P 25/00 (2018.01)] 11 Claims
 
1. A method for treating a memory-related disease or disorder associated with acetyl-CoA synthetase 2 (ACSS2), the method comprising administering a composition comprising an inhibitor of ACSS2 to a subject in need thereof;
wherein the inhibitor of ACSS2 is a small molecule;
wherein the small molecule is selected from the group consisting of a compound having the structure of:

OG Complex Work Unit Chemistry
wherein X41 is selected from the group consisting of O and S;
R41 is selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, unsubstituted aryl, heteroaryl, and combinations thereof, wherein R41 may be optionally substituted; and
R42 and R43 are each independently selected from the group consisting of phenyl and thiophenyl; and

OG Complex Work Unit Chemistry
wherein the memory-related disease or disorder associated with acetyl-CoA synthetase 2 (ACSS2) is an addiction to at least one selected from the group consisting of alcohol, tobacco, cocaine, and opioids.